Pathwork Dx Inks Deal with Kindstar to Offer Tissue of Origin Test in China | GenomeWeb

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced a deal to offer its Pathwork Tissue of Origin Test for cancer diagnosis in China.

The deal with Kindstar Global, which claims to be the largest esoteric diagnostic testing business in China, expands the Redwood City, Calif.-based company's international network of test and service providers, Pathwork said. The agreement is the first international in vitro diagnostic deal for the company, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.